Genesis Geometric Medicine Framework v4: A Four-Part Series on Lo-Shu Projection Theory in Pharmacology — Prodrug Activation, Oncology Target Classification, Drug-Target Matching, and TCGA Mutation Escape Analysis

This four-paper series presents the Genesis Geometric Medicine Framework v4, applying Lo-Shu Projection (LSP) theory to pharmacological problems across four domains. Paper 1 (PAI v3): Side-chain PSA predicts nitroimidazole anaerobic potency (sc_PSA vs MIC90: rho=-0.769, p<0.001, n=21). Paper 2: Tumor target Yin/Yang classification — Yang targets (alpha-helix rich, Q>5.10) are druggable; Yin targets (beta/disordered, Q<4.90) are undruggable (Mann-Whitney p=0.0005, n=25). Paper 3: Oncology drug-target geometric compatibility — Match Score vs |GII_drug - GII_target|: rho=-0.971, p<0.001 (n=29 FDA-approved drugs). Paper 4: TCGA GEI landscape — 45 driver mutations classified into 5 geometric escape categories; threshold |GEI|=0.030 identifies 12 high-priority unmet clinical needs. All descriptors (Q_LTE, GII, sc_PSA, GEI) are parameter-free and derived from Lo-Shu SVD symmetry (sigma1=15, sigma2=4*sqrt(3), sigma3=2*sqrt(3)).